179 related articles for article (PubMed ID: 18722003)
1. Pre-clinical studies of plasmin: superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator.
Marder VJ
Thromb Res; 2008; 122 Suppl 3(Suppl 3):S9-S15. PubMed ID: 18722003
[TBL] [Abstract][Full Text] [Related]
2. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
Stewart D; Kong M; Novokhatny V; Jesmok G; Marder VJ
Blood; 2003 Apr; 101(8):3002-7. PubMed ID: 12446443
[TBL] [Abstract][Full Text] [Related]
3. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
[TBL] [Abstract][Full Text] [Related]
4. A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion.
Shlansky-Goldberg RD; Matsumoto AH; Baumbach GA; Siegel JB; Raabe RD; Murphy TP; Deng C; Ray Dawkins J; Marder VJ
J Thromb Haemost; 2008 Jun; 6(6):944-50. PubMed ID: 18384651
[TBL] [Abstract][Full Text] [Related]
5. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
[TBL] [Abstract][Full Text] [Related]
6. Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results.
Marder VJ; Comerota AJ; Shlansky-Goldberg RD; Davis JP; Deng C; Hanna K; Fineberg D
J Thromb Haemost; 2012 Jun; 10(6):985-91. PubMed ID: 22487025
[TBL] [Abstract][Full Text] [Related]
7. [Thrombolytic agents].
Nagao T
Nihon Rinsho; 2014 Jul; 72(7):1254-7. PubMed ID: 25163317
[TBL] [Abstract][Full Text] [Related]
8. Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis.
Novokhatny V; Taylor K; Zimmerman TP
J Thromb Haemost; 2003 May; 1(5):1034-41. PubMed ID: 12871374
[TBL] [Abstract][Full Text] [Related]
9. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
10. Comparison of local thrombolytic efficacy of plasmin and rt-PA in an in-vitro flow system; a pilot study.
Bizjak N; Bajd F; Vidmar J; Blinc A; Marder VJ; Novokhatny V; Serša I
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):711-4. PubMed ID: 23751605
[TBL] [Abstract][Full Text] [Related]
11. Thrombolysis with plasmin: implications for stroke treatment.
Marder VJ; Jahan R; Gruber T; Goyal A; Arora V
Stroke; 2010 Oct; 41(10 Suppl):S45-9. PubMed ID: 20876504
[TBL] [Abstract][Full Text] [Related]
12. Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential.
Marder VJ; Novokhatny V
J Thromb Haemost; 2010 Mar; 8(3):433-44. PubMed ID: 19943877
[TBL] [Abstract][Full Text] [Related]
13. Thrombolytic therapy for deep vein thrombosis: potential application of plasmin.
Marder VJ
Thromb Res; 2009; 123 Suppl 4():S56-61. PubMed ID: 19303506
[TBL] [Abstract][Full Text] [Related]
14. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding.
Weitz JI
J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):19S-23S. PubMed ID: 8770837
[TBL] [Abstract][Full Text] [Related]
15. New developments in thrombolytic therapy.
Collen DC; Gold HK
Thromb Res Suppl; 1990; 10():105-31. PubMed ID: 2180114
[TBL] [Abstract][Full Text] [Related]
16. Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
Novokhatny VV; Jesmok GJ; Landskroner KA; Marder VJ; Zimmerman TP
Trends Pharmacol Sci; 2004 Feb; 25(2):72-5. PubMed ID: 15102492
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.
Ferres H
Drugs; 1987; 33 Suppl 3():33-50. PubMed ID: 3315613
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
Collen D
J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D; Lijnen HR
Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
[TBL] [Abstract][Full Text] [Related]
20. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
